

Uterine Fibroid Embolization Device market growth analysis with investment opportunities

The Business Research Company's Uterine Fibroid Embolization Device Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 5, 2024 /EINPresswire.com/ -- The uterine fibroid embolization device market has experienced robust growth in recent years, expanding from \$5.3 billion in 2023 to \$5.62 billion in 2024

at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing incidence of uterine fibroids, preference for non-surgical alternatives, awareness and education initiatives, focus on women's health, shift towards outpatient procedures, physician training programs.



You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs "

The Business Research company

Strong Future Growth Anticipated

The uterine fibroid embolization device market is projected to continue its strong growth, reaching \$6.75 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing awareness of non-invasive treatments, global expansion of healthcare services, rise in female healthcare initiatives, integration with multidisciplinary care,

expansion of outpatient services.

Explore comprehensive insights into the global uterine fibroid embolization device market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=13551&type=smp

Growth driver of the uterine fibroid embolization device market

The growing demand for minimally invasive surgeries is expected to propel the growth of the uterine fibroid embolization device market going forward. Minimally invasive surgeries refer to surgical approaches that use small incisions or natural body openings to access and treat



The Business Research Company

Uterine Fibroid Embolization Device Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

internal structures, organs, or tissues to minimize trauma to the patient's body. Uterine fibroid embolization devices are essential tools that enable minimally invasive surgeries to treat uterine fibroids effectively. These specialized devices are meticulously designed to minimize invasiveness by using small incisions, reducing the impact on surrounding tissues. They cater to the increasing demand for less invasive medical procedures, ultimately improving patient outcomes.

Order your report now for swift delivery:

<https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report>

Major Players and Market Trends

Key players in the uterine fibroid embolization device market include Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation.

Major companies operating in the uterine fibroid embolization device market are developing innovative products such as the TruClear system to address the growing need for minimally invasive treatments for uterine fibroids and improve the safety and efficacy of treatment for uterine fibroids. The TruClear system is a mechanical hysteroscopic tissue removal system that is used to treat intrauterine abnormalities (IUA). It is a flexible catheter that is inserted into the uterus through the cervix.

Segments:

- 1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques
- 2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment
- 3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Geographical Insights: North America Leading the Market

North America was the largest region in the uterine fibroid embolization device market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding healthcare facilities and increasing awareness of the benefits of uterine fibroid embolization device.

Uterine Fibroid Embolization Device Market Definition

A uterine fibroid embolization device is a medical device that is used to treat noncancerous tumors using a minimally invasive process. Uterine fibroids are noncancerous growths of the uterus. This device restricts blood supply to uterine fibroids, causing them to shrink and

eventually disappear.

The main types of technologies in uterine fibroid embolization devices are surgical techniques, laparoscopic techniques, ablation techniques and embolization techniques. Surgical techniques refer to the specific methods and procedures used by medical professionals. It is used in various modes of treatment, such as invasive treatment, minimally invasive treatment and non-invasive treatment and it includes a variety of end users, such as hospitals, clinics, and ambulatory surgical centers.

Uterine Fibroid Embolization Device Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Uterine Fibroid Embolization Device Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on [uterine fibroid embolization device market size](#), uterine fibroid embolization device market drivers and trends, uterine fibroid embolization device market major players, competitors' revenues, market positioning, and market growth across geographies. The [uterine fibroid embolization device market report](#) helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Interventional Cardiology Devices And Equipment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report>

Implantable Drug Delivery Devices Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report>

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/725323431>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.